POM vs YJ
Pomdoctor Ltd. and Yunji Inc., side by side — 3 fiscal years reported in CNY, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | POM | YJ |
|---|---|---|
| Revenue | CNY 399.9M | CNY 317.0M |
| Net income | CNY -130.9M | CNY -133.3M |
| Gross margin | · | 44.4% |
| Net margin | · | −42.0% |
| Return on equity | · | −13.2% |
| Diluted EPS | −CNY 21.96 | −CNY 0.07 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | CNY -149.5M | CNY -126.6M |
| Equity | CNY -454.0M | CNY 935.2M |
| Net debt / equity | · | −0.07× |
| Current ratio | 0.48× | 1.41× |
| Revenue CAGR 5y | · | −43.5% |
| Profit CAGR 5y | · | · |
POM bills 1.3× the revenue of YJ, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
Revenue by year
3 years side by side
| Fiscal year | POM | YJ |
|---|---|---|
| FY2025 | CNY 399.9M | CNY 317.0M |
| FY2024 | CNY 342.6M | CNY 417.7M |
| FY2023 | CNY 304.9M | CNY 640.2M |
Net income by year
Bottom line
| Fiscal year | POM | YJ |
|---|---|---|
| FY2025 | CNY -130.9M | CNY -133.3M |
| FY2024 | CNY -37.4M | CNY -123.1M |
| FY2023 | CNY -36.9M | CNY -165.1M |
More in this industry